» Articles » PMID: 30470170

The Role of Advanced Glycation End-products in the Development of Coronary Artery Disease in Patients with and Without Diabetes Mellitus: a Review

Overview
Journal Mol Med
Publisher Biomed Central
Date 2018 Nov 25
PMID 30470170
Citations 127
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Traditional risk factors are insufficient to explain all cases of coronary artery disease (CAD) in patients with diabetes mellitus (DM). Advanced glycation end-products (AGEs) and their receptors may play important roles in the development and progression of CAD. BODY: Hyperglycemia is the hallmark feature of DM. An increase in the incidence of both micro-and macrovascular complications of diabetes has been observed with increased duration of hyperglycemia. This association persists even after glycemic control has been achieved, suggesting an innate mechanism of "metabolic memory." AGEs are glycated proteins that may serve as mediators of metabolic memory due to their increased production in the setting of hyperglycemia and generally slow turnover. Elevated AGE levels can lead to abnormal cross linking of extracellular and intracellular proteins disrupting their normal structure and function. Furthermore, activation of AGE receptors can induce complex signaling pathways leading to increased inflammation, oxidative stress, enhanced calcium deposition, and increased vascular smooth muscle apoptosis, contributing to the development of atherosclerosis. Through these mechanisms, AGEs may be important mediators of the development of CAD. However, clinical studies regarding the role of AGEs and their receptors in advancing CAD are limited, with contradictory results.

Conclusion: AGEs and their receptors may be useful biomarkers for the presence and severity of CAD. Further studies are needed to evaluate the utility of circulating and tissue AGE levels in identifying asymptomatic patients at risk for CAD or to identify patients who may benefit from invasive intervention.

Citing Articles

Impaired microcirculation in the skin and subclinical atherosclerosis in individuals with dysglycaemia in a large population-based cohort.

Cederqvist J, Radholm K, Nystrom F, Engvall J, Bergstrand S, Fredriksson I Cardiovasc Diabetol. 2025; 24(1):86.

PMID: 39985089 PMC: 11846392. DOI: 10.1186/s12933-025-02628-5.


Effect of Mesenchymal Stem Cell-Derived Extracellular Vesicles Induced by Advanced Glycation End Products on Energy Metabolism in Vascular Endothelial Cells.

Liang J, Cheng S, Song Q, Tang Y, Wang Q, Chen H Kidney Int Rep. 2025; 10(1):227-246.

PMID: 39810759 PMC: 11725971. DOI: 10.1016/j.ekir.2024.10.015.


Association between triglyceride-glucose index and in-hospital all-cause mortality under different glucose metabolism status among patients with coronary artery disease.

Meng X, Wang X, Feng B, Zhao Z, Song Q, Xu W BMC Public Health. 2024; 24(1):3051.

PMID: 39501313 PMC: 11536897. DOI: 10.1186/s12889-024-20551-4.


Modulation of circulating levels of advanced glycation end products and its impact on intima-media thickness of both common carotid arteries: CORDIOPREV randomised controlled trial.

Gutierrez-Mariscal F, Lopez-Moreno A, Torres-Pena J, Gomez-Luna P, Arenas-de Larriva A, Romero-Cabrera J Cardiovasc Diabetol. 2024; 23(1):361.

PMID: 39402581 PMC: 11475769. DOI: 10.1186/s12933-024-02451-4.


Association between endothelial function and skin advanced glycation end-products (AGEs) accumulation in a sample of predominantly young and healthy adults.

Fewkes J, Dordevic A, Murray M, Williamson G, Kellow N Cardiovasc Diabetol. 2024; 23(1):332.

PMID: 39251982 PMC: 11386354. DOI: 10.1186/s12933-024-02428-3.


References
1.
Arsov S, Graaff R, van Oeveren W, Stegmayr B, Sikole A, Rakhorst G . Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Clin Chem Lab Med. 2013; 52(1):11-20. DOI: 10.1515/cclm-2012-0832. View

2.
Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V . Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002; 99(24):15596-601. PMC: 137762. DOI: 10.1073/pnas.242407999. View

3.
Raghav A, Ahmad J, Alam K . Nonenzymatic glycosylation of human serum albumin and its effect on antibodies profile in patients with diabetes mellitus. PLoS One. 2017; 12(5):e0176970. PMC: 5435419. DOI: 10.1371/journal.pone.0176970. View

4.
Semba R, Ferrucci L, Sun K, Beck J, Dalal M, Varadhan R . Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res. 2009; 21(2):182-90. PMC: 2684987. DOI: 10.1007/BF03325227. View

5.
Falcone C, Emanuele E, DAngelo A, Buzzi M, Belvito C, Cuccia M . Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005; 25(5):1032-7. DOI: 10.1161/01.ATV.0000160342.20342.00. View